Overview
Thymosin Alpha-1 (Tα1) is a naturally occurring 28-amino-acid peptide originally isolated from thymic tissue by Allan Goldstein and colleagues at George Washington University in 1977. It is produced by the thymus gland — the organ responsible for T-cell maturation and immune education — and plays a foundational role in the development and maintenance of cellular immunity.
Marketed as Zadaxin (SciClone Pharmaceuticals), Tα1 is approved in over 35 countries for the treatment of hepatitis B, hepatitis C, and as an adjunct to antifungal therapy in immunocompromised patients. It is widely used in Asian markets (particularly China, Italy, and parts of Eastern Europe) for immune restoration in oncology, infection, and aging. In the United States, it is not FDA-approved but is prescribed off-label by integrative and functional medicine physicians.
Mechanism of Action
T-Cell Maturation: Tα1 promotes the differentiation and maturation of T-lymphocyte precursors within the thymus, restoring T-cell populations that decline with age (thymic involution) or disease-related immunosuppression.
TLR/MyD88 Signaling: Tα1 activates Toll-like receptors (TLR2 and TLR9) and downstream MyD88 adaptor protein signaling — triggering innate immune responses including NK cell activation and dendritic cell maturation.
Th1/Th2 Balance: Tα1 promotes a Th1 cytokine profile (IL-2, IFN-γ) important for antiviral and antitumor immunity, while potentially helping regulate the Th2-dominated immune dysregulation seen in chronic disease and aging.
Dendritic Cell Function: Promotes maturation and antigen-presenting capacity of dendritic cells, the critical interface between innate and adaptive immunity.
Clinical Research & Evidence
Evidence Level: 🟡 EL2 — Significant human trial data; approved in multiple countries
| Study | N | Indication | Finding |
|---|---|---|---|
| Zhang et al. 2006 | 271 | HBV | Higher HBeAg seroconversion vs. control |
| Cheng et al. 2005 | 180 | HCV | Improved viral response when combined with interferon |
| Garaci et al. 2012 | 886 | Lung cancer + chemo | Survival benefit over chemotherapy alone |
| Romani L. 2008 | Invasive aspergillosis | ~100 | Improved outcomes in immunocompromised patients |
| COVID-19 (retrospective) | Various | Sepsis/ARDS | Multiple Chinese retrospective studies showed reduced mortality |
Dosing (Clinical Protocols)
Standard (Zadaxin protocols):
- 1.6 mg subcutaneous, twice weekly
- Duration depends on indication: 6 months for hepatitis B; continuous in some immune deficiency applications
- Often used in 6-week cycles in off-label immune optimization protocols
Side Effects & Contraindications
Generally very well-tolerated:
- Injection site reactions (most common)
- Transient fever (rare)
- No significant hepatotoxicity or nephrotoxicity in trials
Contraindications:
- Organ transplant recipients on immunosuppression (Tα1 could antagonize immunosuppression)
- Active autoimmune conditions — theoretical concern about immune upregulation
Legal & Regulatory Status
| Region | Status |
|---|---|
| United States | Not FDA approved; off-label use by prescription |
| China / Italy | Approved for hepatitis B, C, and immune deficiency |
| 35+ countries | Approved under Zadaxin brand |
Research Citations
- Goldstein AL, et al. Isolation of a polypeptide that has lymphocyte-differentiating properties and is present in the thymus. PNAS. 1972.
- Zhang W, et al. Thymosin α-1 improves the immune response to HBsAg. Eur J Gastroenterol Hepatol. 2006.
- Garaci E, et al. Thymosin α1 in the treatment of cancer. Ann NY Acad Sci. 2012.
- Romani L, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism. J Clin Invest. 2008.